Citations

Clear

19 citation(s) found for "Shain, Kenneth".

Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI)
Joiner, Laura, Pasvolsky, Oren, Afrough, Aimaz, Zanwar, Saurabh, Banerjee, Rahul, Cassano, Raffaella Cassano, Gaballa, Mahmoud, Julian, Kelley, Grajales-Cruz, Ariel, Alsina, Melissa, Goel, Utkarsh, Corraes, Andre, Dima, Danai, Rana, Masooma, Hosoya, Hitomi, Mikkilineni, Lekha, Fogel, Lindsay, Raza, Shahzad, Ali, Hossam M., Sannareddy, Aishwarya, Sborov, Douglas, Borogovac, Azra, Janakiram, Murali, Davis, James, Green, Kimberly, Biran, Noa, Hassan, Hamza, Herr, Megan, Shune, Leyla, Bhurtel, Evguenia, Atrash, Shebli, Ferreri, Christopher, Midha, Shonali, Nadeem, Omar, Puglianini, Omar Alexis Castaneda, Shain, Kenneth, Abid, Muhammad Bilal, Voorhees, Peter, Khouri, Jack, Portuguese, Andrew, Lin, Yi, Sidana, Surbhi, Hansen, Doris, Patel, Krina, Costa, Luciano, Bal, Susan, Anderson, Larry, Sidana, Surbhi , Hosoya, Hitomi , Davis, James A. , Ali, Hossam M. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Ali, Hossam M , Sannareddy, Aishwarya , Joiner, Laura, Pasvolsky, Oren, Afrough, Aimaz, Zanwar, Saurabh, Banerjee, Rahul, Cassano, Raffaella Cassano, Gaballa, Mahmoud, Julian, Kelley, Grajales-Cruz, Ariel, Alsina, Melissa, Goel, Utkarsh, Corraes, Andre, Dima, Danai, Rana, Masooma, Mikkilineni, Lekha, Fogel, Lindsay, Raza, Shahzad, Ali, Hossam M., Sborov, Douglas, Borogovac, Azra, Janakiram, Murali, Davis, James, Green, Kimberly, Biran, Noa, Hassan, Hamza, Herr, Megan, Shune, Leyla, Bhurtel, Evguenia, Atrash, Shebli, Ferreri, Christopher, Midha, Shonali, Nadeem, Omar, Puglianini, Omar Alexis Castaneda, Shain, Kenneth, Abid, Muhammad Bilal, Voorhees, Peter, Khouri, Jack, Portuguese, Andrew, Lin, Yi, Hansen, Doris, Patel, Krina, Costa, Luciano, Bal, Susan, Anderson, Larry

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 827-827

10.1182/blood-2025-827 Get It

Abstract Background Talquetamab (talq) is a GPRC5D-directed bispecific antibody (BsAb) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). The pivotal monumenTAL-1 clinical trial did not include patients with renal impairment (RI, creatinine clearance<40 mL/min) and therefore, data for the use of this agent in RI is lacking. Methods We examined the outcomes of patients with RRMM treated with standard of care (SOC) talq in a multicenter, retrospective cohort study. RI was defined as creatinine clearance (CrCl) <40 mL/min. For each patient we recorded demographics, disease characteristics, prior therapies, incidence and severity of adverse events of special interest, namely cytokine release syndrome (CRS) and immune-cell associated neurotoxicity syndrome (ICANS), along with response, progression-free (PFS) and overall survival (OS). We compared binary variables between different groups using Chi-squared test and assessed progression free survival (PFS) and overall survival (OS) using Kaplan Meier and Cox proportional hazards models. Patients who received talq as a bridge therapy prior to chimeric antigen receptor T-cells (CART cells) were censored for PFS analysis at the time of subsequent therapy. Results We included 417 patients who received SOC Talq and had complete datasets. 91 (22%) had RI, including 20 (5%) on dialysis. The median age was 68 and 65 years for patients with and without RI. Patients with RI were more likely to be female (64% vs. 51%), less likely to have prior CART cells (35% vs. 48%). There were no differences in performance status, race, presence of high-risk cytogenetic abnormalities [del17p, t(4;14), t(14;16), gain/amplification 1q], lines of prior therapy (median 6 vs. 6), prior ASCT (68% vs. 72%), presence of CNS disease (4% vs. 4%), prior plasma cell leukemia (8% vs 9%), prior BCMA therapy (54% vs. 61%) and triple class refractory disease (90% vs. 94%) among patients with and without RI. Rates of CRS (63% vs. 56%, P=0.21) were similar in the two groups, while severe CRS (grade ≥3: 6% vs 2%, P=0.02) was more common in patients with RI. Any grade (20% vs 14%, P=0.21) and high grade ICANS (grade ≥3: 4% vs 4%, P=0.97) were similar in patients with and without RI. There was no difference between groups on risk of infection (P=0.65) with cumulative risk at 6 months of 39% vs. 40%. With 11.1 months of median follow up, the overall response rate (60% vs 67%; P = 0.12), and progression-free survival (median 7.3 vs. 6.5 mo.; P = 0.9) were comparable between the two groups. There was no difference in outcomes according to RI in both patients previously treated with BCMA-directed therapy and BCMA-naïve. Conversely, among patients with RI, median PFS was 4.6 and 8.5 mo. for patients with and without prior BCMA therapy. Similarly, among patients without RI, median PFS was 6.5 and 6.2 mo, respectively. Among BCMA-naïve patients, there was no difference in OS between patients with and without RI (median not reached, 12 mo. OS rate 71% vs. 73%, P=0.53), while among patients with prior BCMA-directed therapy there was a trend towards better OS for patients without RI (median 8.9 vs. 13.8 mo; 12 mo. OS rate 43% vs 59%, P=0.06). Five patients (25%) became dialysis independent following talq therapy. On multivariable analysis, ECOG >1 (HR 1.62, 95% C.I. 1.25-2.10, P<0.001) and deletion of 17p (HR 1.55, 95% C.I. 1.17-2.06, P=0.003) but not RI or prior BCMA-directed therapy affected PFS. OS was affected by ECOG >1 (HR 2.37, 95% C.I 1.71-3.30, P<0.001), triple-class refractoriness (HR 3.03, 95% C.I. 1.12-8.21, P=0.03) and prior BCMA-directed therapy (HR 1.79, 95% C.I. 1.24-2.59, P=0.002) but not by RI. Conclusion Our findings support the feasibility of talq in patients with RI, including those on dialysis, with similar safety and efficacy profile to patients without RI. While neither prior BCMA-directed therapy nor RI affect PFS, refractoriness to conventional agents and prior exposure to BCMA-directed therapy adversely affects OS. This observation likely reflects better post progression survival following talq due to the availability of efficacious therapeutic options, including those directed at BCMA.
Genomics Define Malignant Transformation in Myeloma Precursor Conditions
Maura, Francesco , Bergsagel, P. Leif , Kumar, Shaji , Maclachlan, Kylee , Derkach, Andriy , Garcés, Juan‐José , Firestone, Ross , Braggio, Esteban , Asmann, Yan W. , Papadimitriou, Marios , Hultcrantz, Malin , Marella, Alessio , Castellano, Giancarlo , Lionetti, Marta , Matera, Antonio , Pioggia, Stefania, Vià, Matteo Da , Magistris, Claudio De, Siegel, Erin M. , Agius, Phaedra , Teer, Jamie K. , Yamashita, Yusuke , Silva, Ariosto S. , Blaney, Patrick , Patel, Krina K. , Campbell, Peter J. , Morgan, Gareth , Orlowski, Robert Z. , Shain, Kenneth H. , Bolli, Niccolò , Bergsagel, P. Leif , Kumar, Shaji K , Maclachlan, Kylee , Derkach, Andriy , Garces, Juan-Jose , Firestone, Ross , Braggio, Esteban , Asmann, Yan, Durante, Michael , Diamond, Benjamin T , Hultcrantz, Malin , Marella, Alessio , Castellano, Giancarlo , Maeda, Akihiro , Lionetti, Marta , Matera, Antonio , Da Vià, Matteo C , de Magistris, Claudio , DeAvila, Danny , Sudalagunta, Praneeth Reddy , Canevarolo, Rafael Renatino , Siegel, Erin M , Teer, Jamie K , McPherson, Andrew , Yamashita, Yusuke , Blaney, Patrick , Baz, Rachid , Patel, Krina , Fonseca, Rafael , Landgren, C Ola , Orlowski, Robert Z. , Shain, Kenneth H , Bolli, Niccolo' , Usmani, Saad , Rajkumar, S Vincent , Maura, Francesco , Ziccheddu, Bachisio , Durante, Michael , Diamond, Benjamin , Leongamornlert, Daniel , Fonseca, Rafaël , Landgren, Ola , Usmani, Saad Z. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | October 8, 2025 | Volume: 44 | Issue: 3 | Pages: 188-199

10.1200/jco-25-01733 | PMID 41061199 Get It

Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). While these precursor conditions are asymptomatic, they are not entirely benign and carry a lifelong risk of progression to MM. Unlike other cancers defined by pathology, malignant transformation from MGUS or SMM to MM has so far relied on demonstration of clinical end-organ damage as morphology and cytogenetics cannot reliably distinguish them. In this study, using genomic data from 374 patients with MGUS or SMM (277 training, 97 validation), to our knowledge, we demonstrate for the first time the ability to identify malignant transformation in MGUS and SMM. We introduce the concept of genomic MM and genomic MGUS to differentiate the subsets of MGUS and SMM that are biologically malignant with genomic features indistinguishable from MM from the subset that is premalignant and unlikely to progress to malignancy. Importantly, we find that most SMM has biological features of malignant transformation indistinguishable from MM. As expected, this subset that we consider having genomic MM is associated with a high risk of progression to MM although some patients remained progression-free beyond 5 years. Conversely, 60% of MGUS and 10% of SMM have no evidence of malignant transformation (genomic MGUS), with no progression during follow-up. Integration of genomic features with the 2/20/20 International Myeloma Working Group model significantly improved the prediction of progression among genomic MM. These findings support the use of genomic criteria to refine the classification and the risk stratification in myeloma precursor conditions.
Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
Vazquez‐Martinez, Mariola , Davis, James A. , Goel, Utkarsh, Afrough, Aimaz , Sannareddy, Aishwarya , Razzo, Beatrice M. , Khouri, Jack , Rana, Masooma , DeJarnette, Shaun, Gaballa, Mahmoud , Avila, Gabriel De, Ouchveridze, Evguenia, Richards, Tiffany, Hosoya, Hitomi , Mikkilineni, Lekha , Schrum, Daniel , Castaneda, Omar, Rossi, Adriana, Forsberg, Peter A. , Lin, Yi, Sborov, Douglas W. , Shain, Kenneth H. , Voorhees, Peter M. , Sidana, Surbhi , Patel, Krina K. , Cowan, Andrew J. , Anderson, Larry D. , Ferreri, Christopher J. , Shune, Leyla , Sidana, Surbhi , Anderson, Larry D , Davis, James A , Hosoya, Hitomi , Dima, Danai , Goel, Utkarsh , Pasvolsky, Oren , Banerjee, Rahul , Grajales‐Cruz, Ariel , Lieberman-Cribbin, Alex , Julian, Kelley , Portuguese, Andrew J. , Susanibar-Adaniya, Sandra P. , Raza, Shahzad , Herr, Megan M. , Ouchveridze, Evguenia, Kaur, Gurbakhash , Puglianini, Omar Castañeda , Rossi, Adriana , Lin, Chenyu , Atrash, Shebli , Richard, Shambavi , Garfall, Alfred L. , Hansen, Doris K. , Lee, Hans C. , Anwer, Faiz

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 897-897

10.1182/blood-2024-203409 Get It

Background: Tec is a BCMA-directed bispecific antibody (BsAb) approved for RRMM after ≥4 prior lines of therapy (LOT) based on the MajesTEC-1 trial. However, patients who had previously received a BCMA-DT were excluded from MajesTEC-1. Herein, we evaluated outcomes of RRMM patients with prior exposure to BCMA-DT treated with standard-of-care Tec. Methods: This was a multicenter retrospective cohort study. We compared variables between different groups using Chi-squared and Kruskal-Wallis tests, and assessed progression free survival (PFS) and overall survival (OS) using Kaplan Meier and Cox proportional hazards model. We used the maximally selected rank statistics method to determine the optimal cut-off point for continuous variables to find the most significant difference in PFS among different groups. Results: A total of 385 patients were included in this study. 193 patients had received a prior BCMA-DT, of whom 77%, 22%, and 1% had received 1, 2, and 3 prior anti-BCMA agents, respectively. In patients who had received a prior BCMA-DT, 35% were aged ≥70 years, 24% had ECOG performance status (PS) ≥2, 61% had high-risk FISH, 32% had extramedullary disease (EMD) at Tec initiation, and 42% were penta-refractory. Compared to the cohort without prior BCMA-DT (n=192), patients who were treated with prior BCMA-DT were more likely to have high risk FISH (61% vs 49%, p=0.02), and higher median number of prior LOT (7 vs 5, p <0.001). The specific types of prior BCMA-DTs with the respective overall response rate (ORR) to the most recent prior BCMA-DT were: antibody drug conjugate only (ADC, n=47, ORR 43%), chimeric antigen receptor T-cell therapy only (CAR T, n=99, ORR 86%), BsAb only (n=6, ORR 100%), ADC + CAR T (n=36, ORR 56%), and other ADC/CAR T/BsAb combinations (n=5, ORR 60%). Median follow up was 9.9 (95% CI:9.5-10.6) months. Patients with prior receipt of BCMA-DT had a lower ORR (51.4% vs 61.5%; p=0.012) and ≥very good partial response rate (39.4% vs 52.6%, p=0.009), but similar ≥complete response rate (22.3% vs 24%; p=0.78) to Tec compared to those without prior BCMA-DT. Moreover, patients with prior BCMA-DT had worse median PFS compared to patients without prior BCMA-DT (prior BCMA-DT: 4.6 months, 95% CI: 2.7-7.5; without prior BCMA-DT: 8.2 months, 95% CI: 5.7-12.2; p=0.017). On multivariable analysis incorporating prior BCMA-DT, age, cytogenetics, EMD, and ECOG PS, receipt of prior BCMA-DT was not independently associated with PFS (HR 1.25, 95% CI 0.95-1.64, p=0.1). The estimated 1-year OS rate was 58.9% (95% CI: 51.64-67.2) for the prior BCMA-DT group vs 65.1% (95% CI: 58.1-73.1) for the group without prior BCMA-DT, p=0.16. For the prior BCMA-DT cohort, response rates to Tec were numerically higher in patients who received CAR T (ORR 51.2%) followed by ADC (ORR 45.5%), and bispecific (ORR 30%) as their most recent prior BCMA-DT (p=0.39). No significant difference in PFS was noted when stratifying patients by number of prior BCMA-DTs, types of all prior BCMA-DTs received, type of most recent prior BCMA-DT, or depth of response to most recent BCMA-DT. Patients who responded to Tec had a numerically longer median time from most recent BCMA-DT exposure to Tec initiation compared to non-responders: 10.5 vs 7.5 months, p=0.48. We found that the optimal cut-off for time from last BCMA-DT exposure to Tec initiation was 8.7 months. Patients with > 8.7 months between last exposure to prior BCMA-DT and Tec initiation had a superior median PFS with Tec (8.1 months, 95% CI: 4.6-11.7) compared to patients with < 8.7 months from last exposure to prior BCMA-DT (2.5 months, 95% CI: 1.1-5.7), p=0.001. The toxicity profile for patients with prior BCMA-DT was similar to those who had not received a prior BCMA-DT. Grade ≥2 CRS occurred in 8.7% vs 13% (p=0.18), and grade ≥2 ICANS in 7.7% vs 6.7%, (p=0.85) of patients with and without prior BCMA-DT, respectively. Patients in the prior BCMA-DT cohort were more likely to have grade 3 thrombocytopenia in the first 30 days after Tec initiation (10.7% vs 6.6%; p=0.08). Conclusion: This is the largest study to date of any BCMA-directed BsAb among BCMA-exposed patients. Receipt of prior BCMA-DT was associated with a trend toward worse PFS, although not statistically significant, and lower likelihood of attaining an overall response. Waiting >9 months between sequencing BCMA therapies may be associated with improved PFS. D.D., M.A.V.M., J.A.D: co first authors; F.A., C.F., L.S.: co senior authors
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Maura, Francesco , Rajanna, Arjun Raj , Ziccheddu, Bachisio , Poos, Alexandra M. , Derkach, Andriy , Maclachlan, Kylee , Durante, Michael , Diamond, Benjamin , Papadimitriou, Marios , Davies, Faith E. , Boyle, Eileen M. , Walker, Brian A. , Hultcrantz, Malin , Silva, Ariosto, Hampton, Oliver , Teer, Jamie K. , Siegel, Erin M. , Bolli, Niccolò , Jackson, Graham , Kaiser, Martin , Cook, Gordon , Kazandjian, Dickran , Stein, Caleb, Chesi, Marta , Bergsagel, Leif, Elias, K. , Goldschmidt, Hartmut , Fenk, Roland , Rhee, Fritz Van, Usmani, Saad Z. , Shain, Kenneth H. , Weinhold, Niels , Bergsagel, P. Leif , Bergsagel, P. Leif , Davies, Faith E , Walker, Brian A , Jackson, Graham H , Pawlyn, Charlotte , Cook, Gordon , Kazandjian, Dickran , Chesi, Marta , Mai, Elias K , Goldschmidt, Hartmut , Weisel, Katja C , Fenk, Roland , Raab, Marc S , van Rhee, Frits , Usmani, Saad , Shain, Kenneth H , Weinhold, Niels , Landgren, C Ola , Bolli, Niccolo' , Boyle, Eileen M , Kaiser, Martin F , Maura, Francesco , Durante, Michael , Maclachlan, Kylee , Derkach, Andriy , Diamond, Benjamin T , Pawlyn, Charlotte , Stein, Caleb, Raab, Marc S. , Morgan, Gareth J. , Landgren, Ola

Mayo Clinic

Journal of Clinical Oncology | January 9, 2024 | Volume: 42 | Issue: 11 | Pages: 1229-1240

10.1200/jco.23.01277 | PMID 38194610 Get It

PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS To decipher and predict the molecular and clinical heterogeneity of NDMM, we assembled a series of 1,933 patients with available clinical, genomic, and therapeutic data. RESULTS Leveraging a comprehensive catalog of genomic drivers, we identified 12 groups, expanding on previous gene expression–based molecular classifications. To build a model predicting individualized risk in NDMM (IRMMa), we integrated clinical, genomic, and treatment variables. To correct for time-dependent variables, including high-dose melphalan followed by autologous stem-cell transplantation (HDM-ASCT), and maintenance therapy, a multi-state model was designed. The IRMMa model accuracy was significantly higher than all comparator prognostic models, with a c-index for OS of 0.726, compared with International Staging System (ISS; 0.61), revised-ISS (0.572), and R2-ISS (0.625). Integral to model accuracy was 20 genomic features, including 1q21 gain/amp, del 1p, TP53 loss, NSD2 translocations, APOBEC mutational signatures, and copy-number signatures (reflecting the complex structural variant chromothripsis). IRMMa accuracy and superiority compared with other prognostic models were validated on 256 patients enrolled in the GMMG-HD6 (ClinicalTrials.gov identifier: NCT02495922 ) clinical trial. Individualized patient risks were significantly affected across the 12 genomic groups by different treatment strategies (ie, treatment variance), which was used to identify patients for whom HDM-ASCT is particularly effective versus patients for whom the impact is limited. CONCLUSION Integrating clinical, demographic, genomic, and therapeutic data, to our knowledge, we have developed the first individualized risk-prediction model enabling personally tailored therapeutic decisions for patients with NDMM.
Outcomes of Patients with Relapsed/Refractory Lymphoplasmacytic Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis
Seif, Sherif , Thapa, Shrinjaya , Zanwar, Saurabh , Cahill, Kirk E. , Treitman, Rachel, Shah, Haikoo, Arora, Shagun , Pongas, Georgios , Winter, Allison , Palomba, Maria Lia, Kapoor, Prashant , Shain, Kenneth H. , Sawalha, Yazeed , Sarosiek, Shayna , Welkie, Rina Li , Major, Ajay , Riedell, Peter A. , Palomba, M. Lia , Grajales‐Cruz, Ariel , Thomas, Sheeba K. , Castillo, Jorge J.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 3045-3045

10.1182/blood-2023-187237 Get It

Background: Data on the clinical activity of venetoclax (ven) in lymphoplasmacytic lymphoma (LPL) are primarily limited to a phase 2 trial of ven monotherapy for a 2-year duration in 32 patients (pts) with relapsed/refractory IgM LPL who received a median of 2 prior treatments (tx), including 16 pts with prior BTK inhibitors (BTKi) (Castillo et al, JCO 2021). Overall response rate (ORR) was 84% and median progression-free survival (PFS) was 30 months (mos). We report the clinical activity of ven and prognostic factors associated with outcomes in a larger cohort. Methods: We included pts with LPL treated with ven alone at 9 US centers. The primary outcome was ORR, which included minor response (MR), partial response (PR), very good PR (VGPR), and complete response (CR) per IWWM-7. Secondary outcomes included PFS, overall survival (OS), safety of ven, and predictors of ORR, PFS, and OS. Results: Sixty-two pts were included. Twenty pts (32%) received ven on a clinical trial. At ven initiation, median age was 65 years (range 38 - 87) , 61% were male, serum monoclonal (M) protein was IgM in 50 pts (91%) (IgG/IgA in 3 (5%), absent in 2 (4%), missing n=7), median hemoglobin (Hb) was 10.4 g/dL (range 5.7-16.4), and median serum IgM was 2580 mg/dL (range 5-9300). Mutations of MYD88 and CXCR4 were present in 52 (95%; missing n = 7) and 19 (38%; missing n = 12) pts, respectively. Median lines of tx (LOT) before ven was 3 (range 1-11, 58% ≥3) including antiCD20 monoclonal antibody n=54 (87%), BTKi n=48 (77%), proteasome inhibitor n=40 (65%), and bendamustine n=31 (50%). Pts who received ven on a clinical trial were less heavily pretreated (median prior LOT = 1.5, 20% ≥3) compared with pts treated off trial (median prior LOT = 4, 76% ≥3). ORR to prior BTKi was 71% (CR 4%, VGPR 10%, PR 35%, MR 21%) (missing n=5), with a median duration of tx of 14 mos (range 0.5-119). BTKi was stopped due to progressive disease (PD) in 60% and toxicity in 40%. ORR to most recent tx before ven was 58% (CR 3%, VGPR 8%, PR 32%, MR 15%); 21% SD, 7% PD, and 15% missing. BTKi was the most frequently used tx immediately before ven (48%). Six pts (10%) required plasmapheresis up to 30 days before starting ven. Median time from diagnosis to ven initiation was 5.9 years (range 0.3-23). Ven starting dose was 200 mg in 33 pts (55%), 20 mg in 11 (18%), and 100 mg in 10 (17%) (other n=6, missing n=2). Ten pts (17%) were admitted for ven tx initiation. Maximum ven dose was 400 mg in 16 (27%) and 800 mg in 38 pts (63%) (other n=6, missing n=2). ORR to ven (missing n=3) was 73% (95% confidence interval [CI] 63-86%) (CR 2%, VGPR 21%, PR 44%, MR 7%); 23% were refractory (SD 13%, PD 10%). Median time to best response was 4 mos (range 0.5-30). Median time to peak Hb was 5 mos (range 0.1-24) and to nadir serum M protein level was 8 mos (range 0.5-34). With a median follow-up of 21.9 mos (range 2.3-70.4), the median and 3-year PFS were 30.4 mos (95% CI 11.0-38.6) and 40% (95% CI 25-54%), respectively (Figure). Median and 3-year OS were not reached (NR) (95% CI NR-NR) and 83% (95% CI 70-91%), respectively. Lymphoma was the most common cause of death (n=8/11, 73%). In univariable analyses (UVA), tx with ven on a clinical trial was associated with higher ORR (90% vs 64%; odds ratio = 8.67, 95% CI 1.04-72.16, p=.046) and superior PFS (median 39 mos (95% CI, 28.4-NR) vs 11 mos (95% CI 6.4-NR), p=.028) without a significant difference in OS. Other factors evaluated in UVA to assess association with ORR, PFS and OS were age at ven start, response to last prior tx, prior tx with BTKi, and CXCR4 mutation status. Of these, receipt of prior tx with BTKi was associated with inferior PFS (HR=2.7, 95% CI 1.1-6.5, p=.024), whereas age >65 years at ven start (HR=8.6, 95% 1.1-67.8, p=0.042) and receipt of ≥3 prior tx (HR=12.0, 95% 1.5-95.9, p=.019) were associated with inferior OS. Four pts (7%) developed laboratory tumor lysis syndrome (TLS) including 2 (3%) with clinical TLS. TLS occurred at the 400 or 800 mg dose in 3 pts (missing n=1). Ven dose interruptions and/or reductions occurred in 39%. Three pts (5%) had febrile neutropenia. Ven was stopped due to PD in 21 pts (34%), planned tx completion in 15 (24%) (median tx duration = 25 mos, range 24-28), toxicity 6 (10%), and other 4 (6%); 16 pts (26%) remain on ven. Median duration of tx for those who stopped ven was 12 mos (range 1-33). Conclusion: Ven is an effective tx option for pts with relapsed or refractory LPL. Compared with the phase 2 study, ORR and PFS were lower in this cohort of more heavily pretreated pts.
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Adekola, Kehinde , Anderson, Larry D. , Costello, Caitlin , Elsedawy, Noura, Faiman, Matthew , Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Sborov, Douglas W. , Shain, Kenneth H. , Weber, Donna, Berardi, Ryan A., Kumar, Shaji , Holmberg, Leona , Anderson, Larry D , Callander, Natalie S. , Baljević, Muhamed , Campagnaro, Erica , Castillo, Jorge J. , Devarakonda, Srinivas , Garfall, Alfred L. , Kang, Yubin , Martin, Thomas G. , Stockerl‐Goldstein, Keith , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 28, 2022 | Volume: 20 | Issue: 1 | Pages: 8-19

10.6004/jnccn.2022.0002 | PMID 34991075 Get It

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specific to the treatment of patients with multiple myeloma in the 2022 version of the guidelines.
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, Shaji , Adekola, Kehinde , Anderson, Larry D. , Castillo, Jorge J. , Chandler, Jason C., Costello, Caitlin , Efebera, Yvonne A. , Faiman, Matthew , Garfall, Alfred L. , Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Shain, Kenneth H. , Sborov, Douglas W. , Stockerl‐Goldstein, Keith , Weber, Donna, Keller, Jennifer , Holmberg, Leona , Castillo, Jorge J , Anderson, Larry D , Garfall, Alfred L , Callander, Natalie S. , Baljević, Muhamed , Campagnaro, Erica , Kang, Yubin , Martin, Thomas G. , Kumar, Rashmi , Stockerl-Goldstein, Keith

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 7, 2020 | Volume: 18 | Issue: 12 | Pages: 1685-1717

10.6004/jnccn.2020.0057 | PMID 33285522 Get It

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, and newly diagnosed multiple myeloma.
IBRUTINIB FOR THE TREATMENT OF BING‐NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY
Buske, Christian , Eyre, Toby A. , Shain, Kenneth H. , Palomba, Lia, Simpson, David , Tedeschi, Alessandra , Ansell, Stephen M. , Nayak, Lakshmi , Castillo, Jorge J. , Itchaki, Gilad , Paludo, Jonas , Varettoni, Marzia , Chavez, Julio C , Issa, Samar , Pasvolsky, Oren , Talaulikar, Dipti , Tam, Constantine S. , Treon, Steven P.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 183-184

10.1002/hon.140_2629 Get It

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
Castillo, Jorge J. , Paludo, Jonas , Varettoni, Marzia , Buske, Christian , Eyre, Toby A. , Chávez, Julio C. , Shain, Kenneth H. , Issa, Samar , Palomba, M. Lia , Pasvolsky, Oren , Simpson, David , Talaulikar, Dipti , Tedeschi, Alessandra , Ansell, Stephen M. , Nayak, Lakshmi , Paludo, Jonas , Buske, Christian , Eyre, Toby A , Chavez, Julio C , Palomba, M Lia , Talaulikar, Dipti , Tam, Constantine S , Tedeschi, Alessandra , Ansell, Stephen M , Treon, Steven , Castillo, Jorge J , Itchaki, Gilad , Tam, Constantine S. , Treon, Steven P. , Varettoni, Marzia , Pasvolsky, Oren

Mayo Clinic

Blood | December 6, 2018 | Volume: 133 | Issue: 4 | Pages: 299-305

10.1182/blood-2018-10-879593 | PMID 30523119 Get It

Abstract The treatment of patients with Bing-Neel syndrome (BNS) is not standardized. We included patients with Waldenström macroglobulinemia (WM) and a radiologic and/or cytologic diagnosis of BNS treated with ibrutinib monotherapy. Response assessment was based on criteria for BNS from the 8th International Workshop for WM. Survival from BNS diagnosis (BNS survival), survival from ibrutinib initiation to last follow-up or death (ibrutinib survival), and time from ibrutinib initiation to ibrutinib discontinuation for toxicity, progression, or death (event-free survival [EFS]) were estimated. Twenty-eight patients were included in our study. The median age at BNS diagnosis was 65 years. Ibrutinib was the first line of treatment for BNS in 39% of patients. Ibrutinib was administered orally at a dose of 560 and 420 mg once daily in 46% and 54% of patients, respectively; symptomatic and radiologic improvements were seen in 85% and 60% of patients within 3 months of therapy. At best response, 85% of patients had improvement or resolution of BNS symptoms, 83% had improvement or resolution of radiologic abnormalities, and 47% had cleared the disease in the cerebrospinal fluid. The 2-year EFS rate with ibrutinib was 80% (95% confidence interval [CI], 58%-91%), the 2-year ibrutinib survival rate was 81% (95% CI, 49%-94%), and the 5-year BNS survival rate was 86% (95% CI, 63%-95%). Ibrutinib therapy is effective in patients with BNS and should be considered as a treatment option in these patients.